The disappointing result means that AZ will be unable to follow in the footsteps of GSK, whose IL-5 inhibitor Nucala ...

AstraZeneca (LON:AZN) said on Wednesday its asthma treatment Fasenra did not meet the primary endpoint in a late-stage trial for patients with chronic obstructive pulmonary disease (COPD).

AstraZeneca (($AZN)) announced an update on their ongoing clinical study. AstraZeneca, in collaboration with Amgen, is ...

In one of the priciest health care deals of 2025, the pharmaceutical giant Merck has acquired the British drugmaker Verona Pharma, which has its U.S. headquarters in Raleigh, for roughly $10 billion.

Patients with COPD are at increased risk for infections, making avoidance and effective treatments key in management.

AstraZeneca said on Wednesday its asthma drug Fasenra failed to control the rate of flare-ups in patients with chronic ...

Among patients with COPD, at least 50% reported that the disease impacts their daily life and emotional health, according to ...

Verona Pharma's stock soars into record territory after buyout deal with Merck Merck & Co. is acquiring Verona Pharma PLC in a $10 billion deal that will expand the pharmaceutical giant's portfolio of ...

In one of the biggest health care deals of 2025, the pharmaceutical giant Merck has acquired the British drugmaker Verona Pharma for roughly $10 billion. Merck announced its purchase of the publicly ...

Chronic obstructive pulmonary disease (COPD) affects millions of Americans, with new data from the National Center for Health Statistics showing the condition becomes increasingly common as people age ...

The likelihood for mortality during hospitalization was increased among those with COPD or asthma vs. asthma-COPD overlap ...